Press Releases Year None201920182017 Turning Point Therapeutics to Host Second Quarter 2019 Conference Call Jul 22, 2019 Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study Jun 20, 2019 Turning Point Therapeutics’ CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference Jun 04, 2019 Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer May 31, 2019 Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor May 15, 2019 Turning Point Therapeutics' CEO to Present at UBS Healthcare Conference May 14, 2019 Turning Point Therapeutics Names Biotech Veteran Patrick Machado, J.D. to Its Board of Directors May 14, 2019 Turning Point Therapeutics and Almac Diagnostic Services Announce Approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the Registrational TRIDENT-1 Clinical Study May 06, 2019 Turning Point Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Apr 22, 2019 Turning Point Therapeutics Announces Pricing of Initial Public Offering Apr 16, 2019 Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 16
Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study Jun 20, 2019
Turning Point Therapeutics’ CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference Jun 04, 2019
Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer May 31, 2019
Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor May 15, 2019
Turning Point Therapeutics Names Biotech Veteran Patrick Machado, J.D. to Its Board of Directors May 14, 2019
Turning Point Therapeutics and Almac Diagnostic Services Announce Approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the Registrational TRIDENT-1 Clinical Study May 06, 2019
Turning Point Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Apr 22, 2019
